Strategy Incorporated Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm Before July 15, 2025 to Discuss Your Rights – MSTR
GlobeNewswire News Room· 2025-06-12 17:10
NEW YORK, June 12, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Strategy Incorporated (NASDAQ: MSTR). Shareholders who purchased shares of MSTR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/strategy-incorporated-loss-submission-form/?id=152598&from=3 CLASS PERIOD: ...
Inditex: Putting This On The Watchlist For Now After Earnings
Seeking Alpha· 2025-06-12 17:09
I am neutral on Industria de Diseño Textil, S.A. ( OTCPK:IDEXY ). My thesis is that while IDEXY is executing extremely well, the current valuation already reflects much of that optimism. With the stock trading at ~23x forward earnings, I believe theI'm a passionate investor with a strong foundation in fundamental analysis and a keen eye for identifying undervalued companies with long-term growth potential. My investment approach is a blend of value investing principles and a focus on long-term growth. I bel ...
Class Action Filed Against Bitfarms Ltd. (BITF) Seeking Recovery for Investors – Contact The Gross Law Firm
GlobeNewswire News Room· 2025-06-12 17:09
NEW YORK, June 12, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Bitfarms Ltd. (NASDAQ: BITF). Shareholders who purchased shares of BITF during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/bitfarms-ltd-loss-submission-form/?id=152596&from=3 CLASS PERIOD: March 21, 2023 to ...
Shareholders that lost money on DoubleVerify Holdings, Inc.(DV) should contact The Gross Law Firm about pending Class Action - DV
GlobeNewswire News Room· 2025-06-12 17:09
NEW YORK, June 12, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of DoubleVerify Holdings, Inc. (NYSE: DV). Shareholders who purchased shares of DV during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/doubleverify-holdings-inc-loss-submission-form-2/?id=152595&from=3 CLASS PER ...
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 7, 2025 in West Pharmaceutical Services, Inc. Lawsuit – WST
GlobeNewswire News Room· 2025-06-12 17:08
NEW YORK, June 12, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of West Pharmaceutical Services, Inc. (NYSE: WST). Shareholders who purchased shares of WST during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/west-pharmaceutical-services-inc-loss-submission-form/?id=152592&fr ...
GTT’s 2025 combined shareholders’ Annual General Meeting summary
Globenewswire· 2025-06-12 17:08
GTT’s 2025 combined shareholders’ Annual General Meeting summary Saint-Rémy-lès-Chevreuse – June 12, 2025. The combined shareholders’ Annual General Meeting (AGM) of GTT (Gaztransport et Technigaz) met yesterday, under the chairmanship of Philippe Berterottière, Chairman and CEO of GTT. Shareholders were not only able to attend the meeting in person, but also to follow it via a live video webcast on the company's website: https://gtt.fr/finance/shareholders-meeting. A replay of the meeting is available at ...
Contact The Gross Law Firm by July 1, 2025 Deadline to Join Class Action Against Civitas Resources, Inc.(CIVI)
GlobeNewswire News Room· 2025-06-12 17:08
NEW YORK, June 12, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Civitas Resources, Inc. (NYSE: CIVI). Shareholders who purchased shares of CIVI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/civitas-resources-loss-submission-form/?id=152593&from=3 CLASS PERIOD: Febru ...
Apple fixes new iPhone zero-day bug used in Paragon spyware hacks
TechCrunch· 2025-06-12 17:06
Researchers revealed on Thursday that two European journalists had their iPhones hacked with spyware made by Paragon. Apple now says it has fixed the bug that was used to hack their phones.Citizen Lab wrote in its report, shared with TechCrunch ahead of its publication, that Apple had told its researchers that the flaw exploited in the attacks had been “mitigated in iOS 18.3.1,” a software update for iPhones released on February 10. Until this week, the advisory of that security update only mentioned one ...
Okta's Backlog Tops $4B on Strong Identity Security Demand
ZACKS· 2025-06-12 17:06
Key Takeaways OKTA's subscription backlog rose 21% to $4.08B. $2.23B in current RPO boosts 12-month revenue visibility. Demand for OKTA's identity tools, like Privileged Access and Okta AI, drives strong enterprise adoption. Despite macro headwinds and rivals like MSFT and CYBR, OKTA projects up to 11% current RPO growth in Q2.Okta’s (OKTA) Remaining Performance Obligations (RPO) or subscription backlog surged to $4.084 billion in the first quarter of fiscal 2026, marking a 21% year-over-year increase. Mo ...
Novo Nordisk to advance subcutaneous and oral amycretin for weight management into phase 3 clinical development
Globenewswire· 2025-06-12 17:06
Bagsværd, Denmark, 12 June 2025 – Novo Nordisk today announced that it will advance subcutaneous and oral amycretin into phase 3 development in weight management based on completed clinical studies. The decision to advance subcutaneous and oral amycretin into phase 3 is based on feedback received from regulatory authorities following end-of-phase 2 interactions for subcutaneous and oral amycretin in weight management. “We are very pleased that the feedback from regulatory authorities has allowed us to take ...